Nektar Therapeutics NKTR Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| —— | -$44.9M+11.7% | -$36.08M— | -$35.52M+4.1% | -$41.59M+20.6% | ||
| —— | $151K-64.6% | $190K-42.8% | $196K-80.3% | $214K-85.3% | ||
| —— | $3.36M-13.9% | $2.19M-54.3% | $3.07M-43.0% | $3.49M-35.7% | ||
| —— | -$934K-115% | -$4.79M-230% | $1.28M-42.8% | -$3.52M-54.7% | ||
| —— | $2.33M+91.4% | -$2.72M— | -$7M-207% | $2.73M-69.6% | ||
| —— | -$949K-116% | $9.86M+306% | $618K-82.7% | $0+100% | ||
| —— | -$1.75M+60.8% | -$1.35M— | -$534K— | -$2.39M— | ||
| —— | -$1.66M-25.6% | -$1.89M-23.1% | -$1.43M+30.6% | -$869K+66.4% | ||
| —— | -$44.3M+9.7% | -$64.96M-40.6% | -$48.76M-11.0% | -$45.74M-21.3% | ||
| —— | $18K+800% | $18K-96.1% | $114K-82.9% | $37K-80.1% | ||
| —— | $452.25M+1,714% | $91.6M+31.2% | $149.56M+714% | $18.92M-72.4% | ||
| —— | $101.48M+46.4% | $91.99M+41.3% | $54.8M-15.9% | $68.57M-19.9% | ||
| —— | -$350.79M-903% | —— | -$94.87M-306% | $49.62M+192% | ||
| $1.07B+506,582% | —— | $410K+394% | $238K+1,731% | $211K+1,011% | ||
| —— | $529.55M+7,564,886% | $38.67M+46,492% | $141.68M+1,089,723% | $211K+1,011% | ||
| —— | $0+100% | $0— | $1K+104% | $6K+700% | ||
| —— | $134.46M+2,610% | -$25.92M-283% | -$1.96M-190% | —— | ||
| —— | $3.36M-13.9% | $2.19M-54.3% | $3.07M-43.0% | $3.49M-35.7% | ||
| —— | -$1.66M-25.6% | -$1.89M-23.1% | -$1.43M+30.6% | -$869K+66.4% | ||
| —— | —— | $0-100% | $0-100% | $0-100% | ||
| —— | -$1.75M+60.8% | -$1.35M— | -$534K— | -$2.39M— | ||
| —— | $2.41M+32.9% | $5.75M+8.8% | $3.83M+11.8% | $3.77M+204% | ||
| —— | $2.33M+91.4% | -$2.72M— | -$7M-207% | $2.73M-69.6% | ||
| —— | -$949K-116% | $9.86M+306% | $618K-82.7% | $0+100% | ||
| —— | $7.94M+59.7% | $9.77M-3.8% | $6.05M+0.4% | $5.39M-15.8% | ||
| —— | $10.86M+3.8% | $21.81M+34.3% | $11.49M-27.0% | $11.18M-33.4% | ||
| —— | $0-100% | —— | —— | —— | ||
| —— | $101.48M+46.4% | $91.99M+41.3% | $54.8M-15.9% | $68.57M-19.9% | ||
| —— | —— | -$174.25K-101% | -$174.25K-101% | -$174.25K-101% | ||
| —— | $25K— | —— | —— | —— | ||
| —— | $4.06M+57,829% | $410K+394% | $238K+1,731% | $211K+1,011% | ||
| —— | —— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | $0-100% | $0-100% | $0-100% | ||
| —— | -$44.32M+9.7% | -$64.98M-39.3% | -$48.88M-9.6% | -$45.78M-20.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.